Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
J Clin Psychiatry 2003;64(6):663-667
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Several clinical and research
applications require an estimation of therapeutic dose
equivalence across antipsychotic medications. Since the advent of
the newer atypical antipsychotics, new dose equivalent
estimations have been needed.
Method: The reported minimum effective dose was
identified for each newer atypical antipsychotic medication and
for haloperidol across all available fixed-dose
placebo-controlled studies. Reported minimum effective dose
equivalence ratios to haloperidol were then converted to
chlorpromazine equivalents using the "2 mg of haloperidol
equals 100 mg of chlorpromazine" convention.
Data Sources and Study Selection: To identify
the fixed-dose studies, the following sources were searched until
June 2002: MEDLINE, the bibliographies of identified reports,
published meta-analyses and reviews, Cochrane reviews, Freedom of
Information Act material available from the Food and Drug
Administration, and abstracts from several scientific meetings
from 1997 to 2002.
Results: Doses equivalent to 100 mg/day of
chlorpromazine were 2 mg/day for risperidone, 5 mg/day for
olanzapine, 75 mg/day for quetiapine, 60 mg/day for ziprasidone,
and 7.5 mg/day for aripiprazole.
Conclusion: These equivalency estimates may be
useful for clinical and research purposes. The source of the dose
equivalency estimation is evidence-based and consistent across